IMMUTEP LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.47 AUD | 0.00% |
|
+4.44% | +36.23% |
| May. 17 | Capital One Initiates Immutep at Overweight Rating With $10 Price Target | MT |
| May. 15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
Presenter SpeechClive Tompkins;Finance News Network (Attendees)Good morning, everyone. Thank y...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.47
AUD
Average target price
0.978
AUD
Spread / Average Target
+108.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.23% | 362M | |
| +41.79% | 50.93B | |
| -0.56% | 42.12B | |
| +49.62% | 42.05B | |
| -7.20% | 29.18B | |
| +12.59% | 26.02B | |
| -21.51% | 18.9B | |
| +6.92% | 13.21B | |
| +24.91% | 12.17B | |
| +29.60% | 12.16B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Transcript : Immutep Limited - Special Call